|
1. Biologie
|
|
|
|
|
Bad Cells. So Many Bad Cells. [In the Pipeline]
|
|
|
|
|
|
The
number of papers citing cell lines that are known to be wrong is
increasing – perhaps not as a percentage of all scientific papers, but
it sure isn’t going down, despite numerous warnings and exhortations.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
NICE shoots down Opdivo again, this time in bladder cancer [FierceBiotech]
|
|
|
|
|
|
Using
its preferred metric, incremental cost-effectiveness ratio (ICER), the
body determined that Opdivo would cost the NHS a base-case £54,220
($71,446) per quality adjusted life year (QALY) that the medication
provides over treatment with chemotherapy med docetaxel and £46,209
($60,890) per QALY versus paclitaxel.
|
|
|
|
|
|
|
NICE no for Opdivo in urothelial carcinoma [PharmaTimes]
|
|
|
|
|
|
NICE
argues that based on the available evidence, it is difficult to
establish the magnitude of the clinical benefit for Opdivo compared with
current clinical practice, given that the drug has not been compared
with existing therapies in studies.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
FDA releases flurry of new, revised drug-specific guidance documents [EndPoints]
|
|
|
|
|
|
The
FDA issued a flurry of product-specific recommendations, providing
guidance for companies looking to develop generic versions of a number
of popular medicines, including Mylan’s EpiPen (epinephrine) alternative
Adrenaclick, Novartis’ cancer treatment Afinitor (everolimus) and
AstraZeneca’s cancer treatment Lynparza (olaparib).
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Taxpayer-funded drugs 'too expensive for patients’ [BBC News]
|
|
|
|
|
|
Pfizer
denied the drug costs £1 per pill. It told the BBC that it took more
than 20 years to build on the work of the Cancer Research UK scientists.
Turning scientific discoveries into medicines takes "billions of pounds
of investment, millions of hours of science and thousands of clinical
trials," the firm explained.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
|
6.5 Médecines alternatives
|
|
|
UC-Irvine, integrative medicine, and the delusion of being “science-based” [Science-Based Medicine]
|
|
|
|
|
|
Last
month, a billionaire couple, Susan and Henry Samueli, announced a $200
million gift to UC-Irvine to found the Susan and Henry Samueli College
of Health Sciences, which will be devoted to integrative medicine and
studying “unconventional” treatments. Its founders promise that it will
be rigorously science-based in articles in a large, glossy magazine.
There are many reasons for doubts about this claim.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Ask The Chefs: Where Does Open Access Go From Here? [The Scholarly Kitchen]
|
|
|
|
|
|
Open
Access (OA) publishing is continuing to grow. Based on our most recent
research and analysis, Delta Think estimates the OA market at
approximately $470M in 2016, up from $390M in 2015. It is also no secret
that OA volume as a percentage of total market volume (estimated at
20-22%) is much higher than OA revenue as a percentage of total market
revenue (4-9%).
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 Controverses
|
|
|
|